Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Payables (2020 - 2025)

Historic Payables for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $6.5 million.

  • Xeris Biopharma Holdings' Payables fell 1240.1% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 1240.1%. This contributed to the annual value of $2.3 million for FY2024, which is 8019.89% down from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Payables of $6.5 million as of Q3 2025, which was down 1240.1% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Payables ranged from a high of $12.1 million in Q3 2023 and a low of $2.3 million during Q4 2024
  • Moreover, its 5-year median value for Payables was $7.1 million (2024), whereas its average is $7.7 million.
  • In the last 5 years, Xeris Biopharma Holdings' Payables skyrocketed by 20842.7% in 2023 and then tumbled by 8019.89% in 2024.
  • Xeris Biopharma Holdings' Payables (Quarter) stood at $8.9 million in 2021, then tumbled by 48.39% to $4.6 million in 2022, then skyrocketed by 151.09% to $11.6 million in 2023, then tumbled by 80.2% to $2.3 million in 2024, then surged by 185.02% to $6.5 million in 2025.
  • Its Payables stands at $6.5 million for Q3 2025, versus $9.5 million for Q2 2025 and $6.4 million for Q1 2025.